IL100502A - PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- - Google Patents

PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-

Info

Publication number
IL100502A
IL100502A IL10050291A IL10050291A IL100502A IL 100502 A IL100502 A IL 100502A IL 10050291 A IL10050291 A IL 10050291A IL 10050291 A IL10050291 A IL 10050291A IL 100502 A IL100502 A IL 100502A
Authority
IL
Israel
Prior art keywords
compound
formula
hepatitis
amino
oxathiolan
Prior art date
Application number
IL10050291A
Other languages
English (en)
Hebrew (he)
Other versions
IL100502A0 (en
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL100502(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919100039A external-priority patent/GB9100039D0/en
Priority claimed from GB919109913A external-priority patent/GB9109913D0/en
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of IL100502A0 publication Critical patent/IL100502A0/xx
Publication of IL100502A publication Critical patent/IL100502A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
IL10050291A 1991-01-03 1991-12-25 PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- IL100502A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919100039A GB9100039D0 (en) 1991-01-03 1991-01-03 Medicaments
GB919109913A GB9109913D0 (en) 1991-05-07 1991-05-07 Medicaments

Publications (2)

Publication Number Publication Date
IL100502A0 IL100502A0 (en) 1992-09-06
IL100502A true IL100502A (en) 1995-12-08

Family

ID=26298202

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10050291A IL100502A (en) 1991-01-03 1991-12-25 PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-

Country Status (23)

Country Link
US (2) USRE39155E1 (el)
EP (2) EP0565549B1 (el)
JP (1) JP2659863B2 (el)
KR (1) KR0156747B1 (el)
AT (1) ATE120644T1 (el)
AU (1) AU660650B2 (el)
CA (2) CA2100269C (el)
CY (1) CY2047B1 (el)
DE (1) DE69201948T2 (el)
DK (1) DK0565549T3 (el)
EE (1) EE02995B1 (el)
ES (1) ES2070628T3 (el)
GE (1) GEP19981482B (el)
GR (1) GR3015694T3 (el)
HK (1) HK159395A (el)
IE (1) IE73642B1 (el)
IL (1) IL100502A (el)
MD (1) MD1224C2 (el)
NO (1) NO180407C (el)
PH (1) PH31397A (el)
TJ (1) TJ249B (el)
TW (1) TW202385B (el)
WO (1) WO1992011852A1 (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
US5932635A (en) * 1991-07-30 1999-08-03 Cytec Technology Corp. Tackified prepreg systems
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
JPH09504785A (ja) 1993-09-10 1997-05-13 エモリー、ユニバーシティー 抗ｂ型肝炎ウイルス活性を有するヌクレオシド
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
CA2203262A1 (en) * 1994-10-22 1996-05-02 Byeong Seon Jeong Nucleoside derivatives and process for preparing thereof
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
EP0831852B1 (en) 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
GB9517022D0 (en) * 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
JP2000515852A (ja) 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
EP0986375A2 (en) 1997-04-07 2000-03-22 Triangle Pharmaceuticals Inc. Use of mkc-442 in combination with other antiviral agents
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
SG132498A1 (en) 1998-08-10 2007-06-28 Idenix Pharmaceuticals Inc Beta-l-2æ-deoxy-nucleosides for the treatment of hepatitis b
DE69942042D1 (de) 1998-11-02 2010-04-01 Gilead Sciences Inc Kombinationstherapie zur Behandlung von Hepatitis B Infektionen
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
KR100927024B1 (ko) 2001-03-01 2009-11-17 아보트 래버러토리즈 시스-ｆｔｃ의 다형 및 기타 결정형
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
AU2003278816A1 (en) 2002-09-13 2004-04-30 Idenix (Cayman) Limited ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
CA2634749C (en) 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
WO2010137027A1 (en) 2009-05-27 2010-12-02 Hetero Research Foundation Solid oral dosage forms of lamivudine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206497B1 (en) * 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
CA1327000C (en) * 1987-08-07 1994-02-15 David L.J. Tyrrell Antiviral therapy for hepatitis b
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
JP2578501B2 (ja) * 1989-03-03 1997-02-05 キヤノン株式会社 電子写真用帯電部材
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
AU5659990A (en) * 1989-05-15 1990-12-18 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Method of treatment of hepatitis
WO1990014091A1 (en) * 1989-05-15 1990-11-29 The United States Of America, Represented By The Secretary, United States Department Of Commerce Method of treatment of hepatitis
DK0479822T3 (da) * 1989-06-27 2000-03-20 Wellcome Found Terapeutiske nucleosider
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
KR910007655A (ko) * 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
EP0560794B1 (en) * 1990-11-13 1996-09-18 Biochem Pharma Inc Substituted 1,3-oxathiolanes with antiviral properties
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
IL101144A (en) * 1991-03-06 1996-09-12 Wellcome Found Pharmaceutical preparations containing 1 -) 2 -) hydroxymethyl (- 1, 3 - oxathiolan-5 - il (5) fluorescitosin and its derivatives for the treatment of their hepatitis B virus infections
GB9105899D0 (en) * 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments

Also Published As

Publication number Publication date
EP0565549A1 (en) 1993-10-20
KR0156747B1 (en) 1998-11-16
EP0565549B1 (en) 1995-04-05
AU660650B2 (en) 1995-07-06
DE69201948T2 (de) 1995-08-03
IE920004A1 (en) 1992-07-15
GEP19981482B (en) 1998-12-25
MD1224B2 (en) 1999-05-31
NO180407C (no) 1997-04-16
DE69201948D1 (de) 1995-05-11
ES2070628T3 (es) 1995-06-01
JPH06507150A (ja) 1994-08-11
US5532246A (en) 1996-07-02
PH31397A (en) 1998-10-29
ATE120644T1 (de) 1995-04-15
IE73642B1 (en) 1997-06-18
USRE39155E1 (en) 2006-07-04
NO932442D0 (no) 1993-07-05
NO932442L (no) 1993-08-26
DK0565549T3 (da) 1995-07-03
IL100502A0 (en) 1992-09-06
TW202385B (el) 1993-03-21
JP2659863B2 (ja) 1997-09-30
MD950086A (ro) 1997-01-31
AU1153492A (en) 1992-08-17
CY2047B1 (en) 1998-04-30
NO180407B (no) 1997-01-06
CA2100269A1 (en) 1992-07-04
HK159395A (en) 1995-10-20
TJ249B (en) 1999-12-23
EE02995B1 (et) 1997-06-16
MD1224C2 (ro) 1999-11-30
EP0494119A1 (en) 1992-07-08
CA2254613A1 (en) 1992-07-04
GR3015694T3 (en) 1995-07-31
CA2100269C (en) 1999-02-23
WO1992011852A1 (en) 1992-07-23

Similar Documents

Publication Publication Date Title
EP0565549B1 (en) Use of 1,3-oxathiolane nucleoside analogues in the manufacture of a medicament for treatment of hepatitis b
EP0515144A1 (en) 1,3-Oxathiolanes useful in the treatment of hepatitis
CA2216634C (en) Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc
WO1997006804A1 (en) 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
IE84837B1 (en) 1,3-oxathiolanes useful in the treatment of hepatitis
US6156737A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
EP1124562B1 (en) Combination therapy to treat hepatitis b virus
EP0639971B1 (en) Therapeutic combinations
AU1765700A (en) Antiviral nucleoside analogues
ZA200505852B (en) Compositions and methods for combination antiviraltherapy
CA2213621A1 (en) Antiviral combinations of bch-189 and ritonavir
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
EP0650363B1 (en) Antiviral combinations
NZ314731A (en) Use of dideoxycytosine derivatives in medicaments for treating hepatitis b viral infections

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired